Reto Thoma
Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.
Urwyler P, Leimbacher M, Charitos P, Moser S, Fehrman-Ekholm I, Trendelenburg M, Thoma R, Sumer J, Camacho-Ortiz A, Bacci M, Huber L, Stüssi-Helbling M, Albrich W, Sendi P, Osthoff M. Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial. Front Immunol 2023; 14:1255292.
27.10.2023Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial.
27.10.2023Front Immunol 2023; 14:1255292
Urwyler Pascal, Leimbacher Marina, Charitos Panteleimon, Moser Stephan, Fehrman-Ekholm Ingela, Trendelenburg Marten, Thoma Reto, Sumer Johannes, Camacho-Ortiz Adrián, Bacci Marcelo R, Huber Lars Chistian, Stüssi-Helbling Melina, Albrich Werner, Sendi Parham, Osthoff Michael
Ward-level risk factors associated with nosocomial coronavirus disease 2019 (COVID-19) outbreaks: A matched case-control study.
Thoma R, Kohler P, Haller S, Männer J, Schlegel M, Flury D. Ward-level risk factors associated with nosocomial coronavirus disease 2019 (COVID-19) outbreaks: A matched case-control study. Antimicrob Steward Healthc Epidemiol 2022; 2:e49.
25.03.2022Ward-level risk factors associated with nosocomial coronavirus disease 2019 (COVID-19) outbreaks: A matched case-control study.
25.03.2022Antimicrob Steward Healthc Epidemiol 2022; 2:e49
Thoma Reto, Kohler Philipp, Haller Sabine, Männer Jasmin, Schlegel Matthias, Flury Domenica
Impact of respirator versus surgical masks on SARS-CoV-2 acquisition in healthcare workers: a prospective multicentre cohort
Haller S, Vuichard-Gysin D, Wiggli B, Besold U, Kuster S, McGeer A, Risch L, Schlegel M, Friedl A, Vernazza P, Kahlert C, Stocker R, Rütti M, Güsewell S, Egger T, Scanferla G, Thoma R, Leal-Neto O, Flury D, Brucher A, Lemmenmeier E, Möller J, Rieder P, Kohler P. Impact of respirator versus surgical masks on SARS-CoV-2 acquisition in healthcare workers: a prospective multicentre cohort. Antimicrob Resist Infect Control 2022; 11:27.
05.02.2022Impact of respirator versus surgical masks on SARS-CoV-2 acquisition in healthcare workers: a prospective multicentre cohort
05.02.2022Antimicrob Resist Infect Control 2022; 11:27
Haller Sabine, Vuichard-Gysin Danielle, Wiggli Benedikt, Besold Ulrike, Kuster Stefan, McGeer Allison, Risch Lorenz, Schlegel Matthias, Friedl Andree, Vernazza Pietro, Kahlert Christian, Stocker Reto, Rütti Markus, Güsewell Sabine, Egger Thomas, Scanferla Giulia, Thoma Reto, Leal-Neto Onicio B, Flury Domenica, Brucher Angela, Lemmenmeier Eva, Möller J Carsten, Rieder Philip, Kohler Philipp
The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature.
Thoma R, Seneghini M, Seiffert S, Vuichard Gysin D, Scanferla G, Haller S, Flury D, Boggian K, Kleger G, Filipovic M, Nolte O, Schlegel M, Kohler P. The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature. Antimicrob Resist Infect Control 2022; 11:12.
21.01.2022The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature.
21.01.2022Antimicrob Resist Infect Control 2022; 11:12
Thoma Reto, Seneghini Marco, Seiffert Salome N, Vuichard Gysin Danielle, Scanferla Giulia, Haller Sabine, Flury Domenica, Boggian Katia, Kleger Gian-Reto, Filipovic Miodrag, Nolte Oliver, Schlegel Matthias, Kohler Philipp
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
Urwyler P, Sendi P, Albrich W, Stüssi-Helbling M, Huber L, Bacci M, Camacho-Ortiz A, Sumer J, Thoma R, Trendelenburg M, Heijnen I, Moser S, Charitos P, Osthoff M. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19). Trials 2021; 22:1.
04.01.2021Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
04.01.2021Trials 2021; 22:1
Urwyler Pascal, Sendi Parham, Albrich Werner, Stüssi-Helbling Melina, Huber Lars C, Bacci Marcelo R, Camacho-Ortiz Adrián, Sumer Johannes, Thoma Reto, Trendelenburg Marten, Heijnen Ingmar A F M, Moser Stephan, Charitos Panteleimon, Osthoff Michael